Takaaki Kobayashi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1597750/publications.pdf

Version: 2024-02-01

77 papers	1,649 citations	279701 23 h-index	360920 35 g-index
77 all docs	77 docs citations	77 times ranked	2163 citing authors

#	Article	IF	Citations
1	Twoâ€year outcomes of lowâ€exposure extendedâ€release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multiâ€center randomized controlled trial. Clinical Transplantation, 2022, , e14655.	0.8	0
2	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 317-324.	0.6	1
3	Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study. International Immunopharmacology, 2021, 91, 107038.	1.7	3
4	Improved detection of donor-specific HLA-class II antibody in kidney transplant recipients by modified immunocomplex capture fluorescence analysis. Transplant Immunology, 2021, 67, 101418.	0.6	0
5	Analysis of T and B Cell Epitopes to Predict the Risk of de novo Donor-Specific Antibody (DSA) Production After Kidney Transplantation: A Two-Center Retrospective Cohort Study. Frontiers in Immunology, 2020, 11, 2000.	2.2	26
6	The effectiveness and safety of computed tomographic peritoneography and video-assisted thoracic surgery for hydrothorax in peritoneal dialysis patients: A retrospective cohort study in Japan. PLoS ONE, 2020, 15, e0238602.	1.1	6
7	Interferonâ€Î³â€induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMGâ€CoA reductase. FEBS Open Bio, 2020, 10, 927-936.	1.0	6
8	Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation. Transplantation Proceedings, 2019, 51, 1378-1381.	0.3	9
9	Current activity of xenotransplantation in Japan. Xenotransplantation, 2019, 26, e12487.	1.6	5
10	Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNÎ³ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation. Therapeutic Drug Monitoring, 2019, 41, 371-375.	1.0	7
11	Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation. Human Immunology, 2019, 80, 169-175.	1.2	10
12	Peripheral blood immune response-related gene analysis for evaluating the potential risk of chronic antibody-mediated rejection. Human Immunology, 2018, 79, 432-438.	1.2	3
13	Inferior long-term graft survival after end-to-side reconstruction for two renal arteries in living donor renal transplantation. PLoS ONE, 2018, 13, e0199629.	1.1	8
14	Increased CD40L+PD-1+ follicular helper T cells (Tfh) as a biomarker for predicting calcineurin inhibitor sensitivity against Tfh-mediated B-cell activation/antibody production after kidney transplantation. International Immunology, 2018, 30, 345-355.	1.8	10
15	MiR-142-5p and miR-486-5p as biomarkers for early detection of chronic antibody-mediated rejection in kidney transplantation. Biomarkers, 2017, 22, 45-54.	0.9	24
16	Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. Transplant Immunology, 2017, 40, 22-30.	0.6	12
17	Regulation of Clinical Xenotransplantationâ€"Time for a Reappraisal. Transplantation, 2017, 101, 1766-1769.	0.5	57
18	Favorable results in <scp>ABO</scp>â€incompatible renal transplantation without B cellâ€targeted therapy: Advantages and disadvantages of rituximab pretreatment. Clinical Transplantation, 2017, 31, e13071.	0.8	26

#	Article	IF	Citations
19	A Single Perioperative Injection of Dexamethasone Decreases Nausea, Vomiting, and Pain after Laparoscopic Donor Nephrectomy. Journal of Transplantation, 2017, 2017, 1-8.	0.3	12
20	Surgical Techniques and Procedures for Kidney Transplant Recipients With Severe Atherosclerosis. Experimental and Clinical Transplantation, 2017, 15, 594-601.	0.2	7
21	Reviewing the pathogenesis of antibodyâ€mediated rejection and renal graft pathology after kidney transplantation. Nephrology, 2016, 21, 4-8.	0.7	16
22	Changes in ABCB1 mRNA Expression in Peripheral Blood Cells before and after Renal Transplantation. Biological and Pharmaceutical Bulletin, 2016, 39, 1085-1090.	0.6	4
23	De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury. Transplantation, 2016, 100, 2194-2202.	0.5	74
24	5Âyear follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment. International Immunopharmacology, 2016, 39, 192-198.	1.7	13
25	First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 1: update on national regulatory frameworks pertinent to clinical is. Xenotransplantation, 2016, 23, 14-24.	1.6	24
26	Association of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 497-504.	2.2	38
27	A Retrospective Study of the Impact of Intraoperative Intact Parathyroid Hormone Monitoring During Total Parathyroidectomy for Secondary Hyperparathyroidism. Medicine (United States), 2015, 94, e1213.	0.4	30
28	Impact of Arterial Reconstruction With Recipient's Own Internal Iliac Artery for Multiple Graft Arteries on Living Donor Kidney Transplantation. Medicine (United States), 2015, 94, e1811.	0.4	13
29	Virus-Associated Hemophagocytic Syndrome in Renal Transplant Recipients: Report of 2 Cases from a Single Center. Case Reports in Hematology, 2015, 2015, 1-4.	0.3	9
30	A proliferation-inducing ligand sustains the proliferation of human naÃ¯ve (CD27â˜) B cells and mediates their differentiation into long-lived plasma cells in vitro via transmembrane activator and calcium modulator and cyclophilin ligand interactor and B-cell mature antigen. Cellular Immunology, 2015, 295, 127-136.	1.4	21
31	Functional Difference Between Membrane-bound and Soluble Human Thrombomodulin. Transplantation, 2015, 99, 702-709.	0.5	11
32	Current status of pig kidney xenotransplantation. International Journal of Surgery, 2015, 23, 229-233.	1.1	31
33	Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Clinical and Experimental Nephrology, 2015, 19, 319-324.	0.7	5
34	Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney International, 2014, 85, 425-430.	2.6	40
35	Herpes Zoster-Attributable Resource Utilization and Cost Burden in Patients With Solid Organ Transplant. Transplantation, 2014, 97, 1178-1184.	0.5	52
36	Influence of olive-derived hydroxytyrosol on the toll-like receptor 4-dependent inflammatory response of mouse peritoneal macrophages. Biochemical and Biophysical Research Communications, 2014, 446, 1225-1230.	1.0	36

#	Article	IF	Citations
37	How to estimate kidney function in kidney transplant recipients with mild to moderate kidney impairment: comparison of estimated glomerular filtration (eGFR) values between creatinine-based GFR equations and cystatin C-based GFR equations for Japanese population. Clinical and Experimental Nephrology, 2014, 18, 130-134.	0.7	12
38	Clinical relevance of post-transplant pharmacodynamic analysis of cyclosporine in renal transplantation. International Immunopharmacology, 2014, 22, 384-391.	1.7	8
39	Role of AMP-Activated Protein Kinase in Ferritin H Gene Expression by Resveratrol in Human T Cells. Biochemistry, 2013, 52, 5075-5083.	1.2	24
40	Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Letters, 2013, 331, 220-229.	3.2	19
41	Frequent development of subclinical chronic antibody-mediated rejection within 1year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Human Immunology, 2013, 74, 1111-1118.	1.2	19
42	AMP-activated protein kinase as a promoting factor, but complement and thrombin as limiting factors for acquisition of cytoprotection: implications for induction of accommodation. Transplant International, 2013, 26, 1138-1148.	0.8	13
43	Kidney Volume Changes in Patients With Autosomal Dominant Polycystic Kidney Disease After Renal Transplantation. Transplantation, 2012, 93, 794-798.	0.5	32
44	Comparative Study on Signal Transduction in Endothelial Cells After Anti-A/B and Human Leukocyte Antigen Antibody Reaction. Transplantation, 2012, 93, 390-397.	0.5	57
45	Significance of <scp>C</scp>4d deposition in antibodyâ€mediated rejection. Clinical Transplantation, 2012, 26, 43-48.	0.8	18
46	Production of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation, 2012, 19, 82-91.	1.6	28
47	Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Human Immunology, 2011, 72, 11-17.	1.2	29
48	Clinical Significance of Regulatory T-Cellâ€"Related Gene Expression in Peripheral Blood After Renal Transplantation. Transplantation, 2011, 91, 191-198.	0.5	40
49	Adiposeâ€derived stromal cells cultured in a lowâ€serum medium, but not bone marrowâ€derived stromal cells, impede xenoantibody production. Xenotransplantation, 2011, 18, 196-208.	1.6	21
50	Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation, 2010, 17, 26-37.	1.6	65
51	Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochemical and Biophysical Research Communications, 2010, 391, 1210-1215.	1.0	32
52	1,25â€dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. Clinical Transplantation, 2009, 23, 368-374.	0.8	11
53	Successful crossâ€breeding of cloned pigs expressing endoâ€Î²â€galactosidase C and human decay accelerating factor. Xenotransplantation, 2009, 16, 511-521.	1.6	23
54	Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo-ÃŸ-galactosidase (ABase) for ABO-incompatible transplantation. Transplant Immunology, 2009, 20, 132-138.	0.6	28

#	Article	IF	Citations
55	Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host. Transplantation, 2009, 88, 380-385.	0.5	101
56	Stimulation Index for PCNA mRNA in Peripheral Blood as Immune Function Monitoring After Renal Transplantation. Transplantation, 2009, 87, 1411-1414.	0.5	11
57	Evaluation of Interleukin-2 mRNA in Whole Blood as a Parameter for Monitoring Cyclosporine Pharmacodynamics. Biological and Pharmaceutical Bulletin, 2009, 32, 604-608.	0.6	10
58	Enzyme-Linked Immunosorbent Assay for Human Leukocyte Antigen Antibody Detection and Urine Protein Test Recommended for Follow-Up Monitoring After Renal Transplantation. Transplantation, 2008, 85, 1595-1600.	0.5	5
59	Alternative Strategy for Overcoming ABO Incompatibility. Transplantation, 2007, 83, 1284-1286.	0.5	9
60	Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. Transplant International, 2007, 20, 365-370.	0.8	2
61	Relation between human decay-accelerating factor (hDAF) expression in pig cells and inhibition of human serum anti-pig cytotoxicity: value of highly expressed hDAF for xenotransplantation. Xenotransplantation, 2007, 14, 67-73.	1.6	17
62	Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transplant International, 2005, 18, 401-407.	0.8	14
63	Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation?. Xenotransplantation, 2004, 11, 247-253.	1.6	98
64	In vivo gene transfer of endo-beta-galactosidase C removes alphaGal antigen on erythrocytes and endothelial cells of the organs. Xenotransplantation, 2004, 11, 444-451.	1.6	15
65	Enzymatic removal of Î±Gal antigen in pig kidneys by ex vivo and in vivo administration of endo-Î²-galactosidase C. Xenotransplantation, 2002, 9, 228-236.	1.6	13
66	Reduction of Î±-galactosyl xenoantigen by expression of endo-Î²-galactosidase C in pig endothelial cells. Xenotransplantation, 2002, 9, 290-296.	1.6	16
67	Prevention of free-radical induced apoptosis by induction of human recombinant Cu, Zn-SOD in pig endothelial cells. Transplant International, 2002, 15, 220-225.	0.8	11
68	Acute humoral rejection of kidney allografts in patients with a positive flow cytometry crossmatch (FCXM). Clinical Transplantation, 2000, 14, 15-20.	0.8	18
69	Comparative study of efficacy of removal of anti-ABO and anti-gal antibodies by double filtration plasmapheresis. Xenotransplantation, 2000, 7, 101-108.	1.6	26
70	Molecular Cloning of Endo-Î²-galactosidase C and Its Application in Removing Î±-Galactosyl Xenoantigen from Blood Vessels in the Pig Kidney. Journal of Biological Chemistry, 2000, 275, 19368-19374.	1.6	51
71	Anti-Gal, Î±-Gal Epitopes, and Xenotransplantation. , 1999, 32, 229-257.		48
72	Î±-Galactosyl Oligosaccharides Conjugated with Polyethylene Glycol as Potential Inhibitors of Hyperacute Rejection upon Xenotransplantation. Biochemical and Biophysical Research Communications, 1997, 232, 731-736.	1.0	21

#	Article	IF	Citations
73	Measurement of portal venous flow velocity with an implantable miniature Doppler probe in pig liver transplantation. Transplant International, 1997, 10, 116-120.	0.8	4
74	Liberation of vasoactive substances and its prevention with thromboxane A2synthase inhibitor in pig liver transplantation. Transplant International, 1996, 9, 76-81.	0.8	4
75	Immunosuppressive drugs and their effect on experimental tumor growth. Transplant International, 1995, 8, 251-255.	0.8	11
76	Enhancement of Tumor Proliferation by Cyclosporine A in Early Phase of Experimental Hepatic Metastasis. Japanese Journal of Cancer Research, 1994, 85, 704-709.	1.7	11
77	A high molecular weight protein in axoplasm underlying excitable membrane of squid giant axon . Biomedical Research, 1983, 4, 615-618.	0.3	5